 |
|
Intravenous Immunoglobulin Treatment Following the First Demyelinating Event Suggestive of Multiple Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Trial
Anat Achiron, MD, PhD;
Irena Kishner, MD;
Ida Sarova-Pinhas, MD;
Havi Raz, BA;
Meir Faibel, MD;
Yael Stern, MD;
Mor Lavie, MA;
M. Gurevich, PhD;
Mark Dolev, MD;
David Magalashvili, MD;
Yoram Barak, MD
Arch Neurol. 2004;61:1515-1520.
Background Intravenous immunoglobulin (IVIg) has been reported to reduce disease activity in patients with relapsing-remitting multiple sclerosis. We assessed the effect of IVIg treatment in patients after the first neurological event suggestive of demyelinative disease and evaluated the occurrence of a second attack and dissemination in time demonstrated by brain magnetic resonance imaging within the first year from onset.
Methods We conducted a randomized, placebo-controlled, double-blind study in 91 eligible patients enrolled within the first 6 weeks of neurological symptoms. Patients were randomly assigned to receive IVIg treatment (2-g/kg loading dose) or placebo, with boosters (0.4 g/kg) given once every 6 weeks for 1 year. Neurological and clinical assessments were done every 3 months, and brain magnetic resonance imaging was performed at baseline and the end of the study.
Results The cumulative probability of developing clinically definite multiple sclerosis was significantly lower in the IVIg treatment group compared with the placebo group (rate ratio, 0.36 [95% confidence interval, 0.15-0.88]; P = .03). Patients in the IVIg treatment group had a significant reduction in the volume and number of T2-weighted lesions and in the volume of gadolinium-enhancing lesions as compared with the placebo group (P = .01, P = .01, and P = .03, respectively). Treatment was well tolerated, compliance was high, and incidence of adverse effects did not differ significantly between groups.
Conclusions Intravenous immunoglobulin treatment for the first year from onset of the first neurological event suggestive of demyelinative disease significantly lowers the incidence of a second attack and reduces disease activity as measured by brain magnetic resonance imaging.
Author Affiliations: Multiple Sclerosis Center (Drs Achiron, Kishner, Sarova-Pinhas, Stern, Gurevich, Dolev, Magalashvili, and Barak and Mss Raz and Lavie) and Neuroradiology Unit (Dr Faibel), Sheba Medical Center, Tel-Hashomer, Israel; and the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel (Drs Achiron, Sarova-Pinhas, Faibel, and Barak).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: A dose-finding trial
Fazekas et al.
Neurology 2008;71:265-271.
ABSTRACT
| FULL TEXT
Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives
Bar-Zohar et al.
Mult Scler 2008;14:719-727.
ABSTRACT
Neurodegenerative central nervous system disease as late sequelae of Langerhans cell histiocytosis. Report from the Japan LCH Study Group
Imashuku et al.
haematol 2008;93:615-618.
ABSTRACT
| FULL TEXT
Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis
Ephrem et al.
Blood 2008;111:715-722.
ABSTRACT
| FULL TEXT
Efficacy of Various Intravenous Immunoglobulin Therapy Protocols in Autoimmune and Chronic Inflammatory Disorders
Gurcan and Ahmed
The Annals of Pharmacotherapy 2007;41:812-823.
ABSTRACT
| FULL TEXT
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
Kappos et al.
Neurology 2006;67:1242-1249.
ABSTRACT
| FULL TEXT
Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis.
Frohman et al.
Arch Neurol 2006;63:614-619.
FULL TEXT
No effect of intravenous immunoglobulins on cytokine-producing lymphocytes in secondary progressive multiple sclerosis
Petereit et al.
Mult Scler 2006;12:66-71.
ABSTRACT
Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis - results of a retrospective multicenter observational study over five years
Haas et al.
Mult Scler 2005;11:562-567.
ABSTRACT
Therapeutic Considerations for Disease Progression in Multiple Sclerosis: Evidence, Experience, and Future Expectations
Frohman et al.
Arch Neurol 2005;62:1519-1530.
ABSTRACT
| FULL TEXT
MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS)
Fazekas et al.
Mult Scler 2005;11:433-440.
ABSTRACT
|
